Guangdong Marubi Biotechnology Co., Ltd. Class A

Guangdong Marubi Biotechnology Co., Ltd. Class A

SSSE:603983
27.47
CNY
+0.74
(+2.77%)
0.36EPS
88.16P/E
12.37BMarket Cap
Apr 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.72
2.97
3.3
3.33
3.77
4.36
4.79
4.36
4.47
4.28
5.58
7.39
8.67
8.07
Basic EPS, GAAP
0.61
0.75
0.78
0.64
0.87
1.15
1.37
1.16
0.62
0.43
0.65
0.85
0.62
0.35
Free Cash Flow per Basic Share
0.72
0.92
0.73
0.57
0.98
1.4
1.22
-0.97
-0.31
-0.15
0.21
-0.04
0.17
- -
Dividend per Share
0.28
0.33
0.47
0.33
0.5
- -
- -
0.39
0.35
0.19
0.27
0.78
0.75
0.5
Book Value per Share
2.52
3.36
1.99
2.3
2.67
3.82
6.66
7.43
7.68
7.94
8.35
8.43
8.31
8.39
Tangible Book Value per Share
2.45
3.29
1.95
2.25
2.62
3.74
6.61
7.38
5.77
6.08
6.55
6.69
7.32
7.43
Basic Weighted Avg Shares
358
362
361
363
359
361
376
400
400
405
399
402
399
402
Sales/Revenue/Turnover
974
1,076
1,191
1,208
1,352
1,576
1,801
1,745
1,787
1,732
2,226
2,970
3,459
3,244
Operating Margin (%)
25.11
27.8
25.04
20.34
25.76
28.86
31.73
27.94
14
10.02
9.01
12.12
7.34
2.48
Depreciation Expense
2
9
14
15
15
15
16
13
20
27
25
28
63
- -
Net Income, GAAP
219
271
281
232
312
415
515
464
248
174
259
342
247
141
Effective Tax Rate (%)
15.37
14.87
14.73
15.11
14.93
15.27
16.48
18.32
22.1
18.95
12.46
10.06
16.57
9.51
Profit Margin (%)
22.45
25.23
23.63
19.22
23.07
26.35
28.59
26.61
13.87
10.06
11.66
11.5
7.15
4.34
Working Capital
163
250
367
510
681
1,082
2,366
1,893
1,399
1,569
1,520
1,358
1,037
1,032
LT Debt
- -
- -
- -
- -
- -
- -
- -
2
15
160
3
2
2
1
Total Equity
453
604
716
828
960
1,382
2,670
3,000
3,158
3,253
3,419
3,447
3,394
3,426
Return on Invested Capital (%)
59.41
45.58
36.53
26.19
32.79
33.52
24.51
15.81
7.25
4.93
7.67
8.57
6.1
- -
Return on Capital (%)
62.22
50.17
40.15
29.39
34.49
35.2
25.52
16.13
8.12
5.48
6.87
8.84
6.24
- -
Return on Common Equity (%)
63.59
51.32
42.63
30.08
34.89
35.56
25.46
16.45
8.18
5.55
7.94
10.16
7.37
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
468
408
456
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
401
401
401
Market Capitalization
10,627
11,284
12,375

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,313
2,274
2,140
Cash, Cash Equivalents & STI
1,659
1,812
1,704
Accounts Receivable, Net
30
28
37
Inventories
225
197
209
Total Current Liabilities
1,177
1,170
1,108
Payables & Accruals
- -
- -
- -
ST Debt
468
408
456
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.38%
2.53%
-1.52%
Free Cash Flow
-110.51%
-200.8%
-533.06%
Net Income, GAAP
4.08%
-4.67%
-27.63%
Sales/Revenue/Turnover
11.88%
15.55%
16.48%
Total Cash Common Dividend
- -
34.8%
-3.92%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
661
691
600
1,017
2,970
2025
847
923
- -
1,009
3,459
2026
881
782
572
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.28
0.16
0.16
0.26
0.85
2025
0.34
0.13
- -
0.01
0.62
2026
0.25
0.14
-0.05
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.52
- -
0.25
0.78
2025
- -
0.5
- -
0.25
0.75
2026
- -
- -
0.25
- -
- -

Company Description

CEO
Huai Qing Sun
Full Time Employees
1,380
Sector
Consumer non-durables
Industry
Household/Personal care
Address
Marubi Building Guangzhou GD China 510308
IPO Date
Jul 25, 2019
Website
marubi.cn
Business
Guangdong Marubi Biotechnology Co., Ltd. is a China-based company primarily engaged in the research, development, design, production, sale, and service of various cosmetics. Its core product portfolio includes eye care products; skin cleansing products; skin care products such as creams, lotions, and masks; and makeup products. The company markets these products under several brand names including Marubi, Cac, and Passional Lover, operating mainly in the domestic Chinese market. Founded in 2002 and headquartered in Guangzhou, Guangdong Province, Marubi has established itself as a significant player in the cosmetics industry within China. Recent developments include a strategic partnership with the German chemicals company Evonik, aimed at advancing the development of the Chinese cosmetics industry through collaboration in raw materials, research, and formulation innovation. This alliance focuses on leveraging mutual expertise to deliver high-performance and sustainable cosmetic products, aligning with Marubi’s commitment to quality and international expansion. Additionally, Marubi plans to issue H-shares and seek a listing on the Hong Kong Stock Exchange to strengthen its capital position and enhance overseas financing capabilities. These moves mark significant strategic expansions beyond its traditional market scope, positioning the company for broader growth and competitiveness in the global cosmetics industry. Guangdong Marubi Biotechnology operates primarily within the cosmetics sector targeting consumer markets interested in skincare, eye care, and makeup products. The company maintains a comprehensive value chain, from research and development to production and sales, encompassing a broad range of cosmetic formulations and applications. Its product innovation and market responsiveness are supported by its collaboration with global chemical industry leaders, reflecting its strategic commitment to advancing product efficacy and sustainability. The company’s headquarters and manufacturing facilities are located in Guangzhou, China, and it employs over one thousand people, supporting a substantial operational scale. This profile reflects Marubi’s evolving business model and market positioning as it pursues growth through partnerships and capital market initiatives.